ISGlobal, Barcelona Institute for Global Health, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain; IGTP Institut d'Investigació Germans Trias I Pujol, Badalona, Barcelona, Spain.
ISGlobal, Barcelona Institute for Global Health, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain; IGTP Institut d'Investigació Germans Trias I Pujol, Badalona, Barcelona, Spain; ICREA, Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.
Curr Top Membr. 2024;94:187-223. doi: 10.1016/bs.ctm.2024.07.003. Epub 2024 Aug 12.
Parasitic diseases constitute a major global health problem, affecting millions of people worldwide. Recent advances in the study of extracellular vesicles (EVs) have opened up new strategies for biomarker discovery in protozoan and helminth infections. Analyses of EVs in cultures and biological fluids have identified numerous potential biomarkers that could be useful for early and differential diagnosis, monitoring therapeutic responses, and the overall management and control of these diseases. Despite the potential of these biomarkers, several challenges must be addressed, including limited research, the need for standardized protocols, and the reproducibility of results across studies. In many parasitic infections, EVs have been obtained from various sample types, including plasma from human patients and mouse models, as well as cultures of the parasites at different stages. EVs were isolated by various methods and predominantly characterized through proteomic analysis or RNA sequencing to assess their cargo and identify potential biomarkers. These biomarker candidates were investigated and validated using different assays such as ELISA, Western Blot, and ROC curves. Overall, the use of EVs is considered a promising new diagnostic strategy for parasite infections, but further research with larger cohorts, standardized methods, and additional validation tests are essential for effective diagnosis and management of these diseases.
寄生虫病是一个全球性的主要健康问题,影响着全世界数百万人。最近在研究细胞外囊泡 (EVs) 方面的进展为原生动物和蠕虫感染的生物标志物发现开辟了新的策略。对培养物和生物液中的 EVs 的分析已经确定了许多潜在的生物标志物,这些生物标志物可能对早期和鉴别诊断、监测治疗反应以及这些疾病的整体管理和控制有用。尽管这些生物标志物具有潜力,但必须解决几个挑战,包括研究有限、需要标准化方案以及研究之间结果的可重复性。在许多寄生虫感染中,已经从各种样本类型中获得了 EVs,包括人类患者和小鼠模型的血浆,以及不同阶段的寄生虫培养物。通过各种方法分离 EVs,并主要通过蛋白质组学分析或 RNA 测序来表征其货物并确定潜在的生物标志物。使用不同的检测方法,如 ELISA、Western Blot 和 ROC 曲线,对这些候选生物标志物进行了研究和验证。总体而言,EVs 的使用被认为是寄生虫感染的一种很有前途的新诊断策略,但需要进行更多的研究,包括更大的队列、标准化的方法和额外的验证测试,以实现这些疾病的有效诊断和管理。